Research Center: San Francisco VA Medical Center
Location: 4150 Clement St, San Francisco, CA 94121, United States
Lead Researcher: Thomas Neylan, MD
IRB: This study has been reviewed and approved by the UCSF IRB plus SFVA Research Subcommittee

Are you a veteran dealing with PTSD symptoms? Your courage has served us; now let’s find new ways to serve you. Researchers at the San Francisco VA Medical Center are conducting a study aimed at exploring a safer, potentially more effective treatment path for those experiencing PTSD symptoms. Your participation could illuminate a path forward, not just for you, but for fellow veterans seeking peace and recovery.

This study centers on evaluating CORT108297, an experimental medication, with a focus on its safety and impact on PTSD symptoms when taken for only seven days. By participating in this study, you’ll contribute to the understanding of the effectiveness of the medication. Your experience could lead to the advancement of this medication as a treatment care option, offering hope and improved quality of life for veterans grappling with the challenges of PTSD. Help researchers better treat PTSD amongst veterans like yourself. Join this study now.

• Participants will receive a new potential treatment for PTSD at no cost.
• Participants will be compensated up to $675 for participating in this study.
• Participants may experience improvements in their PTSD symptoms.
• Participants will be contributing valuable information that may benefit other veterans and civilians with PTSD in the future.
• Participants will be helping to advance medical research.

• Participation is voluntary. If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

• Individuals aged 18 to 75 years who are diagnosed with PTSD OR have symptoms of PTSD
• Must be a military veteran
• Must be willing to use effective means of contraception throughout the duration of the study
• Must be not taking one of the prohibited medications for this trial, and must be willing to stay on a stable dose of certain other medications.
• Must not have a substance or alcohol use disorder in the past 3 months
• Must not have experienced a potentially traumatic event in the last 3 months
• Must not have any medical conditions that require the use of corticosteroids
• Must be available between 10-12 weeks for remote and in-person study assessments.
• Must come to the San Francisco VA Medical Center for 5 different occasions happening within a 2-week period

The study team will provide you with more study details but some things to note:

• Participants will undergo a series of study assessments including clinical interviews, self-report questionnaires, medical assessments including EKG and blood pressure, blood draw, and urine screen. Some participants will be asked to complete a one-night sleep apnea test at home.
• You will participate in study assessments before, during, and after taking the 7 days of medication.
• You will be asked to take the study medication (CORT108297) or a placebo (a pill that looks like the study medication but has no medication in it) once a day for seven days.

San Francisco VA Medical Center
At San Francisco VA Health Care System, our mission is to honor Veterans, their families, and caregivers by offering exceptional care that improves their health and well-being. With an unparalleled reputation as providers of the most complex care across VHA, we have a long history of conducting cutting-edge research, establishing innovative medical programs, and providing compassionate care. Notably, for over 60 years, the San Francisco VA Medical Center’s affiliation with the University of California, San Francisco (UCSF) ensures that all physicians are jointly recruited with the UCSF School of Medicine.

Please note:
Due to the COVID-19 pandemic, the researchers would like to assure the participants that ensuring their and the study staff’s safety is of utmost importance.